vorinostat has been researched along with Diabetes Mellitus, Type 1 in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat treatment increased the frequency of functional regulatory T-cell subsets and their transcription factors Gata3 and FoxP3 in parallel to a decrease in inflammatory dendritic cell subsets and their cytokines IL-6, IL-12, and TNF-α." | 1.40 | Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection. ( Aikin, RA; Billestrup, N; Birkbak, N; Blaabjerg, L; Christensen, DP; Dahllöf, MS; Dinarello, CA; Fossati, G; Grunnet, LG; Gysemans, C; Lundh, M; Mandrup, S; Mandrup-Poulsen, T; Mascagni, P; Mathieu, C; Monzani, V; Noesgaard, D; Paraskevas, S; Piemonti, L; Schmidt, SF; Workman, CT, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabrera, SM | 1 |
| Colvin, SC | 1 |
| Tersey, SA | 1 |
| Maier, B | 1 |
| Nadler, JL | 1 |
| Mirmira, RG | 1 |
| Christensen, DP | 1 |
| Gysemans, C | 1 |
| Lundh, M | 1 |
| Dahllöf, MS | 1 |
| Noesgaard, D | 1 |
| Schmidt, SF | 1 |
| Mandrup, S | 1 |
| Birkbak, N | 1 |
| Workman, CT | 1 |
| Piemonti, L | 1 |
| Blaabjerg, L | 1 |
| Monzani, V | 1 |
| Fossati, G | 1 |
| Mascagni, P | 1 |
| Paraskevas, S | 1 |
| Aikin, RA | 1 |
| Billestrup, N | 1 |
| Grunnet, LG | 1 |
| Dinarello, CA | 1 |
| Mathieu, C | 1 |
| Mandrup-Poulsen, T | 1 |
2 other studies available for vorinostat and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluati | 2013 |
Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection.
Topics: Animals; Cell Line; Chromatin; Cytokines; Diabetes Mellitus, Type 1; Disease Models, Animal; Epigene | 2014 |